Companies / VLS
VITA LIFE SCIENCES LIMITED..
ASX:VLSPharmaceuticals, Biotechnology & Life Sciences54.4M shares on issueAppendix 2A · as of 18 June 2026$2.50price · delayed$137.8Mmarket cap · indicative
A
Dilution grade
No major dilution pressure signals in current disclosures
Cash runwayno data — not a quarterly (4C/5B) cash filer
Share-count growth (24m)-3.4%
Raise cadence (24m)0 cash raises
Options & rights overhang3.7% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone
VITA LIFE SCIENCES LIMITED.. had 54M ordinary shares as of June 2026, a decline of 3.4% between June 2024 and June 2026. There were no capital raises in the 24-month window. Options and rights could convert into 2M new shares, equal to 3.7% of the current share count, with 0% of current shares in the money. The company does not have a current quarterly cash report on record, so no quarterly cash balance or funding-runway figure is disclosed. No proposed securities issues (Appendix 3B) are pending.
AI-generated summary of this page's cited filings · updated 28 July 2026
3.7%
Max option dilution
0.0%
ITM option dilution
0
Raises · last 12 months
—
Cash cover · not a quarterly filer
Shares on issue — last 2 years
Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 54.4M per Appendix 2A (18 June 2026).
Cash runway
Not a quarterly cash filer. This company does not lodge Appendix 4C/5B quarterly cash reports, so cash runway does not apply.
Issuance timeline
Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | Total on issue after | Source |
|---|---|---|---|---|
| 2 July 2026 | 3H · cancellation | VLS : ORDINARY FULLY PAID | 54.4M | Appendix 3H |
| 18 June 2026 | 2A · quoted issue | VLS : ORDINARY FULLY PAID | 54.4M | Appendix 2A |
| 8 June 2026 | 3G · unquoted | VLS : ORDINARY FULLY PAID | 54.2M | Appendix 3G |
| 8 June 2026 | 3G · unquoted | VLS : ORDINARY FULLY PAID | 54.2M | Appendix 3G |
| 21 May 2026 | 3H · cancellation | VLS : ORDINARY FULLY PAID | 54.2M | Appendix 3H |
Paid plan
Full issuance history
Join the waitlist
Capital raises
No equity raises in the last 24 months.
Paid plan
Full raise history
Join the waitlist
Pending proposed issues
No proposed issues (Appendix 3B) currently pending.
Options & convertible securities
3.7%
Total overhang · of current shares
0.0%
In the money · at current price
2.0M
Potential new shares
—
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Join the waitlist
Director dealings
Ownership
Free account
Top-20 holders & substantial holder notices
Sign up free — coming soon
Latest announcements
29 June 2026Update - Notification of buy-back - VLS
28 June 2026Update - Notification of buy-back - VLS
18 June 2026Cleasing Statement
18 June 2026Application for quotation of securities - VLS
11 June 2026Update - Notification of buy-back - VLS
9 June 2026Change of Director's Interest Notice
5 June 2026Change of Director's Interest Notice
1 June 2026On Market Share Buy Back
1 June 2026Notification of buy-back - VLS
29 May 2026Change of Director's Interest Notice
28 May 2026AGM Address and Presentation
21 May 2026Update - Notification of buy-back - VLS
19 May 2026Update - Notification of buy-back - VLS
Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.